In order to test the hypothesis that SRC activity was responsible for MEKi/ERKi resistance, we treated isogenic CRC cell lines +/– PTPRS with an ERK inhibitor in the presence or absence of dasatinib, an inhibitor of SRC. The gene discussed is PTPRS; the disease is colorectal carcinoma.